Eton Pharmaceuticals, Inc.
ETON · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $22 | $19 | $17 | $12 |
| % Growth | 18.7% | 9.5% | 48.4% | – |
| Cost of Goods Sold | $15 | $7 | $7 | $5 |
| Gross Profit | $8 | $12 | $10 | $6 |
| % Margin | 35% | 63% | 57.1% | 55.6% |
| R&D Expenses | $1 | $4 | $1 | -$1 |
| G&A Expenses | $8 | $10 | $9 | $7 |
| SG&A Expenses | $8 | $10 | $9 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $13 | $10 | $6 |
| Operating Income | -$1 | -$1 | -$0 | $1 |
| % Margin | -6.1% | -7.8% | -2.7% | 5.4% |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$1 |
| Pre-Tax Income | -$2 | -$3 | -$1 | -$1 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$2 | -$3 | -$2 | -$1 |
| % Margin | -8.6% | -13.7% | -9.1% | -5.1% |
| EPS | -0.07 | -0.096 | -0.059 | -0.023 |
| % Growth | 27.2% | -64.3% | -155.5% | – |
| EPS Diluted | -0.07 | -0.096 | -0.059 | -0.023 |
| Weighted Avg Shares Out | 27 | 27 | 27 | 26 |
| Weighted Avg Shares Out Dil | 27 | 27 | 27 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | $0 | -$0 | $1 | $1 |
| % Margin | 1.2% | -2.5% | 3.1% | 8.4% |